drugset / Trial / NCT03922880
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This study is measuring the safety of the study drug, ADI-PEG 20, combined with immunotherapy drugs nivolumab and ipilimumab in treating patients with advanced uveal melanoma.
Timeline
- Start
- 2019-04-16
- Primary completion
- 2023-01-20
- Completion
- 2023-01-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Subject | Pegargiminase | Protein / enzyme biologic | 36 mg/m2 | Intramuscular |